For more information from the National Cancer Institute about multiple myeloma and other plasma cell neoplasms, see the following:
Multiple Myeloma/Other Plasma Cell Neoplasms Home Page
What You Need to Know About™ Multiple Myeloma
Drugs Approved for Multiple Myeloma and Other Plasma Cell Neoplasms
Targeted Cancer Therapies
Understanding Cancer Series: Targeted Therapies (Advances in Targeted Therapies and Targeted Therapies for Multiple Myeloma)
Bone Marrow Transplantation a...
Margin-negative local excision, attempting to maintain function.
Sentinel node procedure, possibly followed by more definitive regional node surgery if positive node(s) are found.
Local and regional nodal radiation, especially if there is concern about the adequacy of the primary tumor excision margin or the risk of local-regional recurrence following the nodal surgery (e.g., multiple primary nodes, extracapsular extension, lymphovascular invasion, and evidence of in-transit metastases).
Treatment options under clinical evaluation:
Systemic chemotherapy might be administered to patients thought to be of the highest risk of recurrence with the understanding that existing data have not proven a clinical survival benefit. Enrollment in clinical trials is encouraged.
Current Clinical Trials
Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with stage III neuroendocrine carcinoma of the skin. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.